Drug Trial Radar · NCT05703971
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
62
Planned (sponsor's estimate)
Start
May 9, 2024
Primary completion
Dec 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- Genprex, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2).
Conditions
- Small Cell Lung Cancer Extensive Stage
Interventions
quaratusugene ozeplasmidBiological
Quaratusugene ozeplasmid is an experimental nonviral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
atezolizumabBiological
Atezolizumab is a monoclonal antibody that belongs to a class of drugs that binds to the programmed death-receptor 1 ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) - Phase 1Time frame: First 21-days at each dose level
- Progression-Free Survival Rate (PFSR) - Phase 2Time frame: 18-weeks from Day 1 of maintenance therapy
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Rocky Mountain Cancer Centers, LLP
Lone Tree, Colorado · Recruiting
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri · Recruiting
Gabrail Cancer Center Research
Canton, Ohio · Recruiting
Oncology_Hematology Care Clinical Trials, LLC
Cincinnati, Ohio · Recruiting
Oncology_Hematology Care Clinical Trials, LLC
Cincinnati, Ohio · Recruiting
Oncology_Hematology Care Clinical Trials, LLC
Cincinnati, Ohio · Recruiting
Oncology_Hematology Care Clinical Trials, LLC
Cincinnati, Ohio · Recruiting
Oncology_Hematology Care Clinical Trials, LLC
Fairfield, Ohio · Recruiting
Willamette Valley Cancer Institute (Oregon)
Eugene, Oregon · Recruiting
Northwest Cancer Specialists, P.C.
Portland, Oregon · Recruiting
Providence Cancer Institute
Portland, Oregon · Recruiting
Northwest Cancer Specialists, P.C.
Portland, Oregon · Recruiting
Northwest Cancer Specialists, P.C.
Tigard, Oregon · Recruiting
Texas Oncology - DFW
Dallas, Texas · Recruiting
Texas Oncology - Northeast Texas
Tyler, Texas · Recruiting
Virginia Cancer Specialists, PC
Fairfax, Virginia · Recruiting
Northwest Cancer Specialists, P.C.
Vancouver, Washington · Terminated
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.